Table 1 Demographic characteristics of study participants
Characteristic | Initial sample | Matched Wuhan-Reference | Matched Omicron-Reference | Matched Wuhan-Omicron | |||||
|---|---|---|---|---|---|---|---|---|---|
Wuhan variant cohort | Omicron variant cohort | Reference cohort | Wuhan variant cohort | Reference cohort | Omicron variant cohort | Reference cohort | Wuhan variant cohort | Omicron variant cohort | |
Number of participants | 453 | 357 | 376 | 279 | 279 | 299 | 299 | 263 | 263 |
Median time from the hospital discharge to the follow-up point (IQR), months | 7.5 (7.3, 7.7)/453 | 6.2 (6.1, 6.3)/357 | 6.2 (6.1, 6.4)/376 | 7.5 (7.3–7.7) | 6.2 (6.1–6.3) | 6.1 (6.1–6.3) | 6.2 (6.1–6.3) | 7.5 (7.3–7.7) | 6.2 (6.1–6.3) |
Length of hospitalisation, days | 7.0 (4.0, 10.0)/453 | 3.3 (1.8, 5.5)/357 | 3.2 (2.0, 5.0)/375 | 7.0 (4.0–9.0) | 3.3 (2.1–5.3) | 3.1 (1.7–5.3) | 3.1 (2.0–5.0) | 7.0 (4.0–10.0) | 3.3 (1.8–5.6) |
Gender, female | 239/453 (53%) | 164/357 (46%) | 190/376 (51%) | 48.4% | 48.4% | 50.7% | 50.7% | 51.7% | 51.7% |
Median age (IQR) at hospital admission, years | 10.3 (2.8, 14.7)/453 | 2.6 (0.8, 7.0)/357 | 4.2 (1.9, 7.8)/376 | 3.9 (1.2–9.5) | 4.2 (1.5–9.4) | 3.3 (1.1–7.6) | 3.4 (1.6–7.4) | 3.6 (1.0–9.1) | 3.4 (1.0–8.9) |
Acute COVID-19 severity | 11/453 (2.4%) | 22/357 (6.2%) | 11/376 (2.9%) | 1.8% | 2.7% | 6.7% | 3.0% | 1.9% | 6.8% |
Comorbidities | |||||||||
 Neurological | 46/440 (10%) | 36/354 (10%) | 20/375 (5.3%) | 10.8% | 5.0% | 10.7% | 5.3% | 10.6% | 10.8% |
 Neurodisability | 13/438 (3.0%) | 16/353 (4.5%) | 6/373 (1.6%) | 3.4% | 1.4% | 4.7% | 1.4% | 3.2% | 5.0% |
 Heart diseases | 22//440 (5.0%) | 14/353 (4.0%) | 16/373 (4.3%) | 4.1% | 4.0% | 4.0% | 4.3% | 4.3% | 3.9% |
 Respiratory diseases (not including asthma) | 16/441 (3.6%) | 13/354 (3.7%) | 5/372 (1.3%) | 3.7% | 1.1% | 3.7% | 1.3% | 2.7% | 3.8% |
 Tuberculosis | 0/353 (0%) | 0/354 (0%) | 0/373 (0%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
 Asthma (physician diagnosed) | 10/441 (2.3%) | 2/353 (0.6%) | 8/372 (2.2%) | 1.1% | 2.5% | 0.3% | 2.0% | 0.4% | 0.4% |
 Allergic rhinitis/hay fever | 44/440 (10%) | 23/355 (6.5%) | 25/373 (6.7%) | 8.1% | 6.2% | 6.1% | 6.1% | 7.4% | 6.2% |
 Food allergy | 69/440 (16%) | 28/351 (8.0%) | 43/372 (12%) | 16.0% | 11.3% | 8.2% | 11.2% | 16.4% | 8.1% |
 Atopic dermatitis/Eczema | 45/441 (10%) | 5/354 (1.4%) | 42/374 (11%) | 10.2% | 11.3% | 1.7% | 11.4% | 10.2% | 1.2% |
 Dermatological problems | 22/441 (5.0%) | 3/353 (0.8%) | 6/372 (1.6%) | 3.3% | 1.8% | 0.7% | 1.7% | 3.1% | 1.1% |
 Gastrointestinal (gut) problems | 56/441 (13%) | 25/353 (7.1%) | 27/373 (7.2%) | 11.4% | 8.0% | 7.2% | 6.4% | 11.8% | 7.6% |
 Haematological conditions | 5/441 (1.1%) | 6/353 (1.7%) | 4/373 (1.1%) | 0.7% | 1.1% | 2.0% | 1.3% | 0.8% | 1.5% |
 Malignancy | 1/441 (0.2%) | 2/352 (0.6%) | 1/374 (0.3%) | 0.0% | 0.4% | 0.7% | 0.3% | 0.0% | 0.8% |
 Immunity problems | 3/441 (0.7%) | 6/353 (1.7%) | 1/374 (0.3%) | 0.7% | 0.4% | 1.7% | 0.0% | 0.8% | 1.9% |
 Genetic | 9/441 (2.0%) | 8/351 (2.3%) | 3/373 (0.8%) | 3.0% | 0.7% | 2.4% | 0.7% | 2.8% | 2.3% |
 Endocrinological conditions | 14/441 (3.2%) | 2/353 (0.6%) | 2/374 (0.5%) | 2.2% | 0.7% | 0.7% | 0.3% | 2.4% | 0.4% |
 Kidney disease | 28/440 (6.4%) | 10/352 (2.8%) | 14/374 (3.7%) | 5.2% | 4.0% | 3.1% | 3.7% | 5.8% | 3.5% |
 Overweight and obesity (as defined by clinical staff) | 14/441 (3.2%) | 1/354 (0.3%) | 7/374 (1.9%) | 1.9% | 2.2% | 0.3% | 1.7% | 1.6% | 0.4% |
 Malnutrition | 10/440 (2.3%) | 8/354 (2.3%) | 20/374 (5.3%) | 1.1% | 5.7% | 2.3% | 5.0% | 0.8% | 2.3% |
 Rheumatologic disorder | 9/439 (2.1%) | 1/353 (0.3%) | 1/374 (0.3%) | 1.9% | 0.4% | 0.3% | 0.3% | 1.6% | 0.4% |
 HIV | 0/440 (0%) | 0/350 (0%) | 0/371 (0%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |